Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Usher Syndrome Type 1B
2024-513500-34-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Sep 2024
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of SAR421869 in Usher syndrome type 1B (USH1B), sponsored by Sanofi. Primary endpoint: Incidence of adverse events. Planned start Sep 2024; status: authorised.
02
Drugs
SAR421869
03
Conditions
Usher syndrome type 1B (USH1B)
Beyond the preview
Go deeper on 2024-513500-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513500-34-00.